Chemotherapy for Gliomas

  • Hanneke ZwinkelsEmail author


Standard treatment approaches for adult gliomas consist of surgery, radiotherapy and chemotherapy, based on the histological diagnosis and molecular profile of the specific glioma. Patient performance status and other prognostic factors are also taken into consideration when deciding upon treatment options.

Temozolomide (TMZ), procarbazine, vincristine and lomustine (PCV) are all types of alkylating (e.g. damaging the DNA, affecting the ability of cancer cells to multiply) chemotherapy agents frequently used in the treatment of gliomas. They can be given as initial treatment (either in combination with or adjuvant to radiotherapy) or administered at recurrence. Oncology specialist nurses work closely together with patients receiving chemotherapy, as well as their caregivers. Effective education by the oncology nurse of the patient and his/her caregiver(s) promotes patient safety and well-being, helps maintain optimal dosing and ensures accurate assessment and evaluation of side effects and toxicities. Specialist nurses evaluate the process and initiate supportive therapies as required, such as fatigue management, nutritional advice, psychosocial support and physiotherapy.

Temozolomide, lomustine and procarbazine can cause myelosuppression (also known as bone marrow suppression) and require careful monitoring of full blood counts to prevent complications associated with neutropenia, thrombocytopenia and lymphopenia. Other side effects such as nausea and fatigue are manageable, neuropathy is a specific side effect of vincristine, but all can have significant impacts on quality of life. These side effects and their nursing implications and considerations will be explored in more detail in this chapter.

Interventions such as treatment delay may lead to recovery of the bone marrow function and blood counts. Dose adjustments—if deemed necessary—may allow the patient to continue chemotherapy treatment as long as there is no evidence of tumour progression during treatment. Should a patient’s tumour progress whilst on active chemotherapy treatment, the treating physicians and specialist nurse will need to help manage the patient’s expectations and adjust their goal settings.


Glioma Patient education Temozolomide Lomustine Side effects Management Thrombocytopenia Lymphopenia Nausea Fertility 


  1. 1.
    Armstrong TS, Gilbert MR. Chemotherapy of astrocytoma: an overview. Semin Oncol Nurs. 1998;14(1):18–25.CrossRefGoogle Scholar
  2. 2.
    Graham CA, Cloughesy TF. Brain tumor treatment: chemotherapy and other new developments. Semin Oncol Nurs. 2004;20(4):260–72.CrossRefGoogle Scholar
  3. 3.
    van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50. Scholar
  4. 4.
    Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ, Kouwenhoven MC, Bernsen HJ, et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer. 2013;49(16):3477–85. Scholar
  5. 5.
    Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43. Scholar
  6. 6.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefGoogle Scholar
  7. 7.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, et al. European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076–84.CrossRefGoogle Scholar
  8. 8.
  9. 9.
    Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. Engl J Med. 2017;376(11):1027–37. Scholar
  10. 10.
    Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55. Scholar
  11. 11.
    Rogers TW, Toor G, Drummond K, Love C, Field K, Asher R, Tsui A, et al. The 2016 revision of the WHO classification of central nervous system tumours: retrospective application to a cohort of diffuse gliomas. J Neurooncol. 2017; Scholar
  12. 12.
    van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, et al. Interim results from the CATNON trial (EORTC study 26053–22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):1645–53. doi: Epub 2017 Aug 8.CrossRefGoogle Scholar
  13. 13.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874–80. Scholar
  14. 14.
    Hollywood E, Semple D. Nursing strategies for patients on oral chemotherapy. Oncology. 2001;15(1 Suppl 2):37–9.PubMedGoogle Scholar
  15. 15.
    Bordonaro S, Raiti F, Di Mari A, Lopiano C, Romano F, Pumo V, Giuliano SR, et al. Active home-based cancer treatment. J Multidiscip Healthc. 2012;5:137–43. Scholar
  16. 16.
    Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003;7(6 Suppl):21–4.CrossRefGoogle Scholar
  17. 17.
    Zwinkels H. The developing role of the neuro-oncology nurse: a Dutch perspective. Br J Neurosci Nurs. 2008;4:390–3.CrossRefGoogle Scholar
  18. 18.
    Zwinkels H, Roon K, Jeurissen FJ, Taphoorn MJ, Hop WC, Vecht CJ. Management of temozolomide toxicity by nurse practitioners in neuro-oncology. Oncol Nurs Forum. 2009;36(2):225–31. Scholar
  19. 19.
    MASCC Oral Agent Teaching Tool. 2009. Accessed 8 Aug 2017.
  20. 20.
    Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7(6 Suppl):5–9.CrossRefGoogle Scholar
  21. 21.
    Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol. 2006;8(3):280–3.CrossRefGoogle Scholar
  22. 22.
    Natelson EA, Pyatt D. Temozolomide-induced myelodysplasia. Adv Hematol. 2010;2010:760402. Scholar
  23. 23.
    Armstrong TS, Cao Y, Scheurer ME, Vera-Bolaños E, Manning R, Okcu MF, Bondy M, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 2009;11(6):825–32. Scholar
  24. 24.
    Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol. 2007;9(1):47–52.CrossRefGoogle Scholar
  25. 25.
    van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715–22.CrossRefGoogle Scholar
  26. 26.
    Lyman GH, Djulbegovic B. The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treat Rev. 2005;31(8):628–39.CrossRefGoogle Scholar
  27. 27.
    Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375–82.CrossRefGoogle Scholar
  28. 28.
    Dittus KL, Gramling RE, Ades PA. Exercise interventions for individuals with advanced cancer: a systematic review. Prev Med. 2017;pii:S0091-7435(17)30262-1. Scholar
  29. 29.
    Zwinkels H, Dörr J, Kloet F, Taphoorn MJ, Vecht CJ. Pregnancy in women with gliomas: a case-series and review of the literature. J Neurooncol. 2013;115(2):293–301. Scholar
  30. 30.
    Dohle GR. Male infertility in cancer patients. Int J Urol. 2010;17:327–31.CrossRefGoogle Scholar
  31. 31.
    Naysmith TE, Blake DA, Harvey VJ, Johnson NP. Do men undergoing sterilizing cancer treatments have a fertile future? Hum Reprod. 1998;13(11):3250–5.CrossRefGoogle Scholar
  32. 32.
    Ducray F, Colin P, Cartalat-Carel S, et al. Management of malignant gliomas diagnosed during pregnancy. Rev Neurol (Paris). 2006;162(3):322–9. (in French)CrossRefGoogle Scholar
  33. 33.
    McGrane J, Bedford T, Kelly S. Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme. Clin Oncol (R Coll Radiol). 2012;24(4):311. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Haaglanden Medisch Centrum, Antonius HoveLeidschendamThe Netherlands

Personalised recommendations